Received Apr 9, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | 2 | MD9SL | — |
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | 1 | — | — |
Engerix-B adult dose to 19-year-old; Engerix-B adult dose to 19-year-old; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of overdose in a 19-year-old female patient who received HBV (Engerix B) (batch number MD9SL, expiry date 08-DEC-2026) for prophylaxis. Co-suspect products included HBV (Engerix B) for prophylaxis. On 24-MAR-2025, the patient received the 2nd dose of Engerix B. On 21-FEB-2025, the patient received the 1st dose of Engerix B. On 21-FEB-2025, not applicable after receiving Engerix B and an unknown time after receiving Engerix B, the patient experienced overdose (Verbatim: Engerix-B adult dose to 19-year-old). On 24-MAR-2025, the patient experienced overdose (Verbatim: Engerix-B adult dose to 19-year-old). The outcome of the overdose and overdose were not applicable. Additional Information: GSK Receipt Date: 24-MAR-2025 The pharmacist called to report the adult dose 20mcg/1ml of Engerix-B was inadvertently administered to a 19-year-old patient for her first and second dose, which led to overdose. Suspect Vaccine Start Date was 2-21-2025.